Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection

Journal of Infectious Diseases

Volumn 188, Issue 5, 2003, Pages 743-752

  Hu, Dong Liang ^a   Omoe, Katsuhiko ^b   Sasaki, Sanae ^a   Sashinami, Hiroshi ^a   Sakuraba, Hirotake ^a   Yokomizo, Yuichi ^c   Shinagawa, Kunihiro ^b   Nakane, Akio ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b IWATE UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF ANIMAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; MUTANT PROTEIN; NEUTRALIZING ANTIBODY; SUPERANTIGEN; TOXIC SHOCK SYNDROME TOXIN 1; TUMOR NECROSIS FACTOR ALPHA;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BACTERIAL COUNT; BACTERIUM MUTANT; CONTROLLED STUDY; DEATH; DOWN REGULATION; INFECTION PREVENTION; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PASSIVE TRANSPORT; PRIORITY JOURNAL; PROVOCATION TEST; SEPSIS; SPLEEN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SURVIVAL; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; BACTERIAL TOXINS; BACTERIAL VACCINES; DISEASE MODELS, ANIMAL; ENTEROTOXINS; IMMUNIZATION, PASSIVE; INTERFERON TYPE II; INTERLEUKIN-10; MICE; MICE, INBRED BALB C; MUTATION; RECOMBINANT PROTEINS; SHOCK, SEPTIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SUPERANTIGENS; VACCINATION;

EID: 0141835875     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/377308     Document Type: Article

References (63)

1. Archer GL. Staphylococcus aureus: a well-armed pathogen. Clin Infect Dis 1998; 26:1179-81.
2. Miles H, Lesser W, Sears P. The economic implications of bioengineered mastitis control. J Dairy Sci 1992; 75:596-605.
3. Fitzgerald JR, Monday SR, Foster TJ, et al. Characterization of a putative pathogenicity island from bovine Staphylococcus aureus encoding multiple superantigens. J Bacteriol 2001; 183:63-70.
4. Kenny K, Reiser RF, Bastida-Corcuera FD, Norcross NL. Production of enterotoxins and toxic shock syndrome toxin by bovine mammary isolates of Staphylococcus aureus. J Clin Microbiol 1993; 31:706-7.
5. Etz H, Minh DB, Henics T, et al. Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus. Proc Natl Acad Sci USA 2002; 99:6573-8.
6. McKenney D, Pouliot KL, Wang Y, et al. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 1999; 284:1523-7.
7. Michie C. Staphylococcal vaccines. Trends Immunol 2002; 23:461-3.
8. Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 2000; 13:16-34.
9. Rasheed JK, Arko RJ, Feeley JC, et al. Acquired ability of Staphylococcus aureus to produce toxic shock-associated protein and resulting illness in a rabbit model. Infect Immun 1985; 47:598-604.
10. Jarraud S, Mougel C, Thioulouse J, et al. Relationships between Staphylococcus aureus genetic background, virulence factors, agr groups (alleles), and human disease. Infect Immun 2002; 70:631-41.
11. Booth MC, Pence LM, Mahasreshti P, Callegan MC, Gilmore MS. Clonal associations among Staphylococcus aureus isolates from various sites of infection. Infect Immun 2001; 69:345-52.
12. Musser JM, Schlievert PM, Chow AW, et al. A single clone of Staphylococcus aureus causes the majority of cases of toxic shock syndrome. Proc Natl Acad Sci USA 1990; 87:225-9.
13. Gampfer J, Thon V, Gulle H, Wolf HM, Eibl MM. Double mutant and formaldehyde inactivated TSST-1 as vaccine candidates for TSST-1-induced toxic shock syndrome. Vaccine 2002; 20:1354-64.
14. Schlievert PM. Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses. J Allergy Clin Immunol 2001; 108:S107-10.
15. Leung DY, Harbeck R, Bina P, et al. Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens. J Clin Invest 1993; 92:1374-80.
16. Kotzin BL, Leung DY, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol 1993; 54:99-166.
17. Takahashi N, Nishida H, Kato H, Imanishi K, Sakata Y, Uchiyama T. Exanthematous disease induced by toxic shock syndrome toxin 1 in the early neonatal period. Lancet 1998; 351:1614-9.
18. Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990; 248:705-11.
19. Jupin C, Anderson S, Damais C, Alouf JE, Parant M. Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon. J Exp Med 1988; 167:752-61.
20. Kum WW, Laupland KB, See RH, Chow AW. Improved purification and biologic activities of staphylococcal toxic shock syndrome toxin 1. J Clin Microbiol 1993; 31:2654-60.
21. Bohach GA, Fast DJ, Nelson RD, Schlievert PM. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 1990; 17:251-72.
22. Kain KC, Schulzer M, Chow AW. Clinical spectrum of nonmenstrual toxic shock syndrome (TSS): comparison with menstrual TSS by multivariate discriminant analyses. Clin Infect Dis 1993; 16:100-6.
23. Crass BA, Bergdoll MS. Involvement of staphylococcal enterotoxins in nonmenstrual toxic shock syndrome. J Clin Microbiol 1986; 23:1138-9.
24. Lee VT, Chang AH, Chow AW. Detection of staphylococcal enterotoxin B among toxic shock syndrome (TSS)- and non-TSS - associated Staphylococcus aureus isolates. J Infect Dis 1992; 166:911-5.
25. Ulrich RG, Olson MA, Bavari S. Development of engineered vaccines effective against structurally related bacterial superantigens. Vaccine 1998; 16:1857-64.
26. Bavari S, Dyas B, Ulrich RG. Superantigen vaccines: a comparative study of genetically attenuated receptor-binding mutants of staphylococcal enterotoxin A. J Infect Dis 1996; 174:338-45.
27. Neill RJ, Jett M, Crane R, et al. Mitogenic activities of amino acid substitution mutants of staphylococcal enterotoxin B in human and mouse lymphocyte cultures. Infect Immun 1996; 64:3007-15.
28. Woody MA, Krakauer T, Ulrich RG, Stiles BG. Differential immune responses to staphylococcal enterotoxin B mutations in a hydrophobic loop dominating the interface with major histocompatibility complex class II receptors. J Infect Dis 1998; 177:1013-22.
29. Drynda A, Konig B, Bonventre PF, Konig W. Role of a carboxy-terminal site of toxic shock syndrome toxin 1 in eliciting immune responses of human peripheral blood mononuclear cells. Infect Immun 1995; 63:1095-101.
30. Cullen CM, Blanco LR, Bonventre PF, Choi E. A toxic shock syndrome toxin 1 mutant that defines a functional site critical for T-cell activation. Infect Immun 1995; 63:2141-6.
31. Earhart CA, Mitchell DT, Murray DL, et al. Structures of five mutants of toxic shock syndrome toxin-1 with reduced biological activity. Biochemistry 1998; 37:7194-202.
32. Bonventre PF, Heeg H, Edwards CK III, Cullen CM. A mutation at histidine residue 135 of toxic shock syndrome toxin yields an immunogenic protein with minimal toxicity. Infect Immun 1995; 63:509-15.
33. Hurley JM, Shimonkevitz R, Hanagan A, et al. Identification of class II major histocompatibility complex and T cell receptor binding sites in the superantigen toxic shock syndrome toxin 1. J Exp Med 1995; 181:2229-35.
34. Bonventre PF, Heeg H, Cullen C, Lian CJ. Toxicity of recombinant toxic shock syndrome toxin 1 and mutant toxins produced by Staphylococcus aureus in a rabbit infection model of toxic shock syndrome. Infect Immun 1993; 61:793-9.
35. Murray DL, Earhart CA, Mitchell DT, Oblendorf DH, Novick RP, Schlievert PM. Localization of biologically important regions on toxic shock syndrome toxin 1. Infect Immun 1996; 64:371-4.
36. Lowell GH, Colleton C, Frost D, et al. Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines. Infect Immun 1996; 64:4686-93.
37. Lowell GH, Kaminski RW, Grate S, et al. Intranasal and intramuscular proteosome-staphylococcal enterotoxin B (SEB) toxoid vaccines: immunogenicity and efficacy against lethal SEB intoxication in mice. Infect Immun 1996; 64:1706-13
38. Woody MA, Krakauer T, Stiles BG. Staphylococcal enterotoxin B mutants (N23K and F44S): biological effects and vaccine potential in a mouse model. Vaccine 1997; 15:133-9.
39. Nakane A, Okamoto M, Asano M, Kohanawa M, Minagawa T. Endogenous gamma interferon, tumor necrosis factor, and interleukin-6 in Staphylococcus aureus infection in mice. Infect Immun 1995; 63:1165-72.
40. Omoe K, Ishikawa M, Shimoda Y, Hu DL, Ueda S, Shinagawa K. Detection of seg, seh, and sei genes in Staphylococcus aureus isolates and determination of the enterotoxin productivities of S. aureus isolates harboring seg, seh, or sei genes. J Clin Microbiol 2002; 40:857-62.
41. Robbins R, Gould S, Bergdoll M. Detecting the enterotoxigenicity of Staphylococcus aureus strains. Appl Microbiol 1974; 28:946-50.
42. Stiles BG, Krakauer T, Bonventre PF. Biological activity of toxic shock syndrome toxin 1 and a site-directed mutant, H135A, in a lipopolysaccharide-potentiated mouse lethality model. Infect Immun 1995; 63:1229-34.
43. Nakane A, Nishikawa S, Sasaki S, et al. Endogenous interleukin-4, but not interleukin-10, is involved in suppression of host resistance against Listeria monocytogenes infection in gamma interferon-depleted mice. Infect Immun 1996; 64:1252-8.
44. Bone RC. Gram-positive organisms and sepsis. Arch Intern Med 1994; 154:26-34.
45. Lee JC. The prospects for developing a vaccine against Staphylococcus aureus. Trends Microbiol 1996; 4:162-6.
46. Greenberg DP, Ward JI, Bayer AS. Influence of Staphylococcus aureus antibody on experimental endocarditis in rabbits. Infect Immun 1987; 55:3030-4.
47. Nilsson IM, Patti JM, Bremell T, Hook M, Tarkowski A. Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death. J Clin Invest 1998; 101:2640-9.
48. McCormick JK, Hirt H, Dunny GM, Schlievert PM. Pathogenic mechanisms of enterococcal endocarditis. Curr Infect Dis Rep 2000; 2:315-21.
49. Schlievert PM, Jablonski LM, Roggiani M, et al. Pyrogenic toxin superantigen site specificity in toxic shock syndrome and food poisoning in animals. Infect Immun 2000; 68:3630-4.
50. Stiles BG, Garza AR, Ulrich RG, Boles JW. Mucosal vaccination with recombinantly attenuated staphylococcal enterotoxin B and protection in a murine model. Infect Immun 2001; 69:2031-6.
51. Nilsson IM, Verdrengh M, Ulrich RG, Bavari S, Tarkowski A. Protection against Staphylococcus aureus sepsis by vaccination with recombinant staphylococcal enterotoxin A devoid of superantigenicity. J Infect Dis 1999; 180:1370-3.
52. Zhao YX, Tarkowski A. Impact of interferon-gamma receptor deficiency on experimental Staphylococcus aureus septicemia and arthritis. J Immunol 1995; 155:5736-42.
53. Zhao YX, Nilsson IM, Tarkowski A. The dual role of interferon-gamma in experimental Staphylococcus aureus septicaemia versus arthritis. Immunology 1998; 93:80-5.
54. Sasaki S, Nishikawa S, Miura T, et al. Interleukin-4 and interleukin-10 are involved in host resistance to Staphylococcus aureus infection through regulation of gamma interferon. Infect Immun 2000; 68:2424-30.
55. Howard M, Muchamuel T, Andrade S, Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993; 177:1205-8.
56. Berg DJ, Kuhn R, Rajewsky K, et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest 1995; 96:2339-47.
57. Florquin S, Amraoui Z, Abramowicz D, Goldman M. Systemic release and protective role of IL-10 in staphylococcal enterotoxin B-induced shock in mice. J Immunol 1994; 153:2618-23.
58. Hasko G, Virag L, Egnaczyk G, Salzman AL, Szabo C. The crucial role of IL-10 in the suppression of the immunological response in mice exposed to staphylococcal enterotoxin B. Eur J Immunol 1998; 28:1417-25.
59. LeClaire RD, Hunt RE, Bavari S. Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination. Infect Immun 2002; 70:2278-81.
60. Meyer RF, Miller L, Bennett RW, MacMillan JD. Development ofa monoclonal antibody capable of interacting with five serotypes of Staphylococcus aureus enterotoxin. Appl Environ Microbiol 1984; 47:283-7.
61. Bohach GA, Hovde CJ, Handley JP, Schlievert PM. Cross-neutralization of staphylococcal and streptococcal pyrogenic toxins by monoclonal and polyclonal antibodies. Infect Immun 1988; 56:400-4.
62. Bavari S, Ulrich RG, LeClaire RD. Cross-reactive antibodies prevent the lethal effects of Staphylococcus aureus superantigens. J Infect Dis 1999; 180:1365-9.
63. Kum WW, Chow AW. Inhibition of staphylococcal enterotoxin A-induced superantigenic and lethal activities by a monoclonal antibody to toxic shock syndrome toxin-1. J Infect Dis 2001; 183:1739-48.